November 18, 2024 7:58am

4 negative closes in a row within 7 November negative closes makes a case for the oversold out of 11 sessions

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

MY Pre-Open Thoughts: 6 Positive, 1 Negative Indications and 1 Sell into Strength

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!

 

RegMed Investors (RMi) <Friday’s> Closing Bell: another wipe-out of value … https://www.regmedinvestors.com/articles/13700

RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Monday: The pre-open Dow futures are DOWN -0.08% (-35 points), the S&P futures are UP +0.12% or (+7 points) and the Nasdaq futures are UP +0.40% or (+80 points)

  • Stock futures were mixed Monday, 11/18,
  • European markets fell,
  • Asia pacific were markets mixed

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

The major averages had been rolling on a postelection rally since x-president Trump’s victory but the upward momentum has been slowing.

Friday, the Dow lost 305.87 points (- 0.70%), the S&P slipped -78.55 points (-1.32%) and the Nasdaq fell 427.53 points (-2.24%).

For the week, the S&P 500 posted a loss of 2.1%, while the Nasdaq slid about 3.2% and the Dow fell 1.2%.

Economic Data Docket: NAHB housing market index, November (42 expected, 43 previously)

 

Q4/24: November 7 negative and 4 positive closes

  • October: 8 positive and 15 negative closes

Q3/24:

  • September – 10 positive and 10 negative close
  • August – I neutral, 10 positive and 11 negative closes
  • July: 1 market holiday. 1 day off, 6 negative, 1 neutral and 12 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context 

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell into Strength:

Friday, Thursday, Wednesday, Tuesday, Monday, Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)         

Mesoblast (MESO) closed down -$1.28 after Thursday’s -$0.39, Wednesday’s +$1.76 after Tuesday’s +$0.22 after Monday’s +$0.55 with a positive +$0.51 or +5.08% aftermarket

 

Positive Indications:

Friday, Thursday, Wednesday, Tuesday, Monday, Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)         

Alnylam Pharmaceuticals (ALNY) closed down -$22.35 after Thursday’s -$5.56, Wednesday’s -$4.35, Tuesday’s -$10.87 and Monday’s +$2.39 with a positive +$0.32 or +0.14% aftermarket

Beam Therapeutics (BEAM) closed down -$2.26 after Thursday’s -$0.31, Wednesday’s -$0.44, Tuesday’s -$2.41, Monday’s +$3.29 with a positive +$0.65 or +2.70% aftermarket

CRISPR Therapeutics (CRSP) closed up +$0.40 after Thursday’s -$2.94, Wednesday’s -$0.94, Tuesday’s -$4.13 and Monday’s +$3.24 with a positive +$0.63 or +1.33% aftermarket

Intellia Therapeutics (NTLA) closed down -$1.15 after Thursday’s-$0.99 after Wednesday’s -$0.54, Tuesday’s -$0.85 and Monday’s +$0.77 with a positive +$0.08 or +0.57% aftermarket

Moderna (MRNA) closed down -$2.92 after Thursday’s -$2.37, Wednesday’s -$1.33, Tuesday’s +$0.72 and Monday’s -$4.08 with a positive +$0.44 or +1.19% aftermarket

Regenxbio (RGNX) closed down -$1.51 after Thursday’s +$1.16, Wednesday’s +$0.18, Tuesday’s -$1.05 and Monday’s +$0.40 with a positive +$0.34 or +3.53% aftermarket

 

Negative Indication:

Friday, Thursday, Wednesday, Tuesday, Monday, Friday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Ultragenyx Pharmaceuticals (RARE) closed down -$2.89 after Thursday’s -$1.07, Wednesday’s +$0.87 and Tuesday’s -$2.89 with a negative -$0.44 or -0.98% aftermarket      

 

The BOTTOM LINE: Been cryin’ a river all last week as earnings season came to a close for my covered companies.

It’s time for the oversold to be recognized, one of my calling cards with words!

“Stocks are starting the week on the back foot as the prospect of higher-for-longer rates holds post-election bullishness in check. The S&P 500 has reversed half of its Trump-fueled rally after sharp weekly losses for the major gauges, led by tech.” <Yahoo Finance>

Ranking the end of October:     

  • 11/15 – Friday: closed negative with 4 incliner, 31 decliners and 1 flat
  • 11/14 – Thursday: closed negative with 3 incliner, 31 decliners and 1 flat
  • 11/13 – Wednesday: closed negative with 8 incliner, 25 decliners and 2 flats
  • 11/12 – Tuesday: closed negative with 7 incliner, 27 decliners and 1 flat
  • 11/11 – Monday closed positive with 23 incliner, 11 decliners and 1 flat
  • 11/8 – Friday: closed negative with 15 incliner, 18 decliners and 2 flats
  • 11/7 – Thursday: closed negative with 11 incliner, 20 decliners and 4 flats
  • 11/6 – Wednesday: closed positive with 26 incliner, 7 decliners and 2 flats
  • 11/5 – Tuesday closed positive with 25 incliner, 8 decliners and 2 flats
  • 11/4 – Monday closed negative with 15 incliner, 18 decliners and 2 flats
  • 11/1 - Friday advance/decline line closed positive with 26 incliner, 7 decliners and 2 flats

 

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.